Mycosis Fungoides / Sézary Syndrome · Brentuximab vedotin monotherapy for CD30+ MF/cutaneous ALCL (1.8 mg/kg IV q3 weeks)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | aggressive |
|---|---|
| Linked regimen | REG-BV-MONO-MF |
| ID | IND-MF-ADVANCED-1L-BV |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-MF-SEZARY |
| Sources | SRC-NCCN-BCELL-2025 |
Notes
STUB. CD30+ aggressive arm; preferred for LCT subset.
Used By
Algorithms
ALGO-MF-SEZARY-1L- ALGO-MF-SEZARY-1LALGO-MF-SEZARY-2L- ALGO-MF-SEZARY-2L